Company Quick10K Filing
Gilead Sciences
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 1,280 $85,862
10-Q 2019-11-05 Quarter: 2019-09-30
10-Q 2019-08-06 Quarter: 2019-06-30
10-Q 2019-05-08 Quarter: 2019-03-31
10-K 2019-02-26 Annual: 2018-12-31
10-Q 2018-11-06 Quarter: 2018-09-30
10-Q 2018-08-06 Quarter: 2018-06-30
10-Q 2018-05-09 Quarter: 2018-03-31
10-K 2018-02-27 Annual: 2017-12-31
10-Q 2017-11-07 Quarter: 2017-09-30
10-Q 2017-08-07 Quarter: 2017-06-30
10-Q 2017-05-10 Quarter: 2017-03-31
10-K 2017-02-27 Annual: 2016-12-31
10-Q 2016-11-07 Quarter: 2016-09-30
10-Q 2016-08-05 Quarter: 2016-06-30
10-Q 2016-05-06 Quarter: 2016-03-31
10-K 2016-02-24 Annual: 2015-12-31
10-Q 2015-11-04 Quarter: 2015-09-30
10-Q 2015-08-05 Quarter: 2015-06-30
10-Q 2015-05-08 Quarter: 2015-03-31
10-K 2015-02-25 Annual: 2014-12-31
10-Q 2014-11-05 Quarter: 2014-09-30
10-Q 2014-08-04 Quarter: 2014-06-30
10-Q 2014-05-07 Quarter: 2014-03-31
10-K 2014-02-25 Annual: 2013-12-31
10-Q 2013-10-31 Quarter: 2013-09-30
10-Q 2013-08-01 Quarter: 2013-06-30
10-Q 2013-05-08 Quarter: 2013-03-31
10-K 2013-02-27 Annual: 2012-12-31
10-Q 2012-11-06 Quarter: 2012-09-30
10-Q 2012-08-01 Quarter: 2012-06-30
10-Q 2012-05-04 Quarter: 2012-03-31
10-Q 2011-11-04 Quarter: 2011-09-30
10-Q 2011-08-05 Quarter: 2011-06-30
10-Q 2011-05-09 Quarter: 2011-03-31
10-K 2011-02-28 Annual: 2010-12-31
10-Q 2010-11-08 Quarter: 2010-09-30
10-Q 2010-08-09 Quarter: 2010-06-30
10-Q 2010-05-10 Quarter: 2010-03-31
10-K 2010-03-01 Annual: 2009-12-31
8-K 2019-10-24 Earnings, Exhibits
8-K 2019-10-15 Officers, Exhibits
8-K 2019-08-23 Other Events, Exhibits
8-K 2019-07-30 Earnings, Exhibits
8-K 2019-07-17 Officers, Exhibits
8-K 2019-07-17 Officers, Exhibits
8-K 2019-07-14 Enter Agreement, Exhibits
8-K 2019-05-23 Officers, Exhibits
8-K 2019-05-08 Amend Bylaw, Shareholder Vote, Exhibits
8-K 2019-05-02 Earnings, Exhibits
8-K 2019-04-30 Officers, Exhibits
8-K 2019-03-01 Officers
8-K 2019-02-04 Earnings, Exhibits
8-K 2018-12-10 Officers, Exhibits
8-K 2018-10-25 Earnings, Exhibits
8-K 2018-09-12 Officers
8-K 2018-08-06 Officers, Exhibits
8-K 2018-07-25 Earnings, Exhibits
8-K 2018-07-23 Officers, Exhibits
8-K 2018-05-09 Officers, Shareholder Vote, Exhibits
8-K 2018-05-01 Earnings, Exhibits
8-K 2018-02-06 Earnings, Exhibits
8-K 2018-01-31 Officers, Exhibits

Gilead Sciences Financials

GILD Metrics, Comps, Filings

Annual | Quarterly

Business

Gilead Sciences, Inc. (Gilead, we, our or us), incorporated in Delaware on June 22, 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we strive to transform and simplify care for people with life-threatening illnesses around the world. We have operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead's primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases. We seek to add to our existing portfolio of products through our internal discovery and clinical development programs, product acquisition, in-licensing and strategic collaborations.

2018 was marked by operational excellence and transition as we positioned ourselves for the future growth of our business. We continued to develop and deliver innovative medicines to help people with life-threatening illnesses around the world. Highlights of our 2018 performance include:

-HIV: We achieved record sales of our HIV products in 2018, with HIV product revenues increasing by 19% in the United States and 12% worldwide compared to 2017. This growth was driven by the successful launch of Biktarvy® and the continued strong uptake of our single tablet regimens containing tenofovir alafenamide (TAF) for the treatment of HIV infection as well as Truvada® for a pre-exposure prophylaxis (PrEP) indication for HIV prevention. Biktarvy, a once-daily single tablet regimen containing bictegravir, emtricitabine and TAF for the treatment of HIV infection in adults, was approved by the U.S. Food and Drug Administration (FDA) in February and by the European Commission in June.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Amgen (AMGN) 113,199 81% 12.4 13% 59,373 48,579 23,562 19,133 7,958 11,144 138,288
Gilead Sciences (GILD) 85,862 79% 9.9 9% 63,210 40,594 22,357 17,630 5,957 10,182 100,705
Biogen Idec (BIIB) 46,443 86% 6.4 20% 26,288 13,339 14,072 12,044 5,294 7,912 50,669
Seattle Genetics (SGEN) 10,884 0% -42.0 -18% 1,568 296 758 0 -280 -258 10,820
Neurocrine Biosciences (NBIX) 8,009 99% 142.2 2% 1,067 583 605 599 18 55 7,862
Bio-Techne (TECH) 7,914 66% 38.0 5% 1,884 719 714 473 96 218 8,306
Qiagen (QGEN) 7,622 0% 5,748 3,113 0 0 0 0 8,637
Bluebird Bio (BLUE) 6,843 97% -10.2 -32% 2,023 387 57 55 -655 -638 6,507
Moderna (MRNA) 4,732 0% -18.0 -16% 1,685 347 65 0 -268 -253 4,568
Autolus Therapeutics (AUTL) 3,969 0% -161.3 -8% 254 22 0 0 -21 -23 3,752
Spark Therapeutics (ONCE) 3,953 37% -16.7 -31% 750 349 58 21 -231 -229 3,827
Repligen (RGEN) 3,939 56% 65.1 2% 1,068 189 233 129 27 57 3,721
Argenx (ARGX) 3,491 0% 578 40 0 0 0 0 3,489
Allogene Therapeutics (ALLO) 3,175 -17.8 -20% 734 78 0 0 -147 -142 2,524
China Biologic Products (CBPO) 2,933 64% 30.5 3% 2,010 165 186 119 69 85 2,594
Iovance Biotherapeutics (IOVA) 2,693 -15.2 -35% 436 39 0 0 -151 -150 2,289
Mesoblast (MESO) 2,543 0% 652 171 0 0 0 0 2,543
Adaptimmune Therapeutics (ADAP) 2,516 0% -27.2 -42% 240 53 42 0 -99 -91 2,477
Halozyme Therapeutics (HALO) 2,380 52% -91.6 -10% 418 158 182 95 -43 -25 2,327
Genetic Technologies (GENE) 2,362 0% 6 1 0 0 0 0 2,357

Balance Sheet ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash1,2739089,8841,8042,1132,1002,7008,2297,58817,940
Accounts Receivable1,3901,6221,9511,7512,1004,6355,8544,5143,8513,327
Inventory1,0528129961,7452,0561,3861,9551,587801814
PP&E7007017741,1001,4721,6742,2762,8653,2954,006
Assets9,69911,59317,30321,24022,49734,66451,83956,97770,28363,675
Accounts Payable8118031,2061,3271,2569551,1781,206814790
Long-Term Debt3,4808,2246,63612,40422,17826,34633,54227,322
Liabilities3,3315,72910,56411,93011,12819,23833,30538,09049,84142,288
Stockholders' Equity6,3675,8646,7399,31011,36915,42618,53418,88720,44221,387
Income Statement ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue6,4697,3908,1029,39810,80424,47432,15130,39026,10722,127
Cost of Revenue4,853
Gross Profit17,274
R&D9401,0731,2291,7602,1202,8543,0145,0983,7345,018
SG&A9471,0441,2421,4611,6992,9833,4263,3983,8784,056
Tax8761,0248621,0381,0512,0603,1372,4363,3422,339
Net Income2,6262,8902,7892,5743,05712,05918,10613,4884,6445,460
Cash Flow ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating3,0802,8343,6393,1953,10512,81820,32916,66911,8988,400
Cash Investing-2,216-1,9383,590-11,846-254-1,823-12,475-11,985-16,06914,355
Cash Financing-1,051-1,3391,764563-2,544-3,025-4,963-9,3473,393-12,318